Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 1
2021 1
2022 1
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Dytfeld D, et al. Among authors: tyczynska a. Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12. Lancet Oncol. 2023. PMID: 36642080 Free PMC article. Clinical Trial.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Kubicki T, Dytfeld D, Wróbel T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ. Kubicki T, et al. Among authors: tyczynska a. Br J Haematol. 2023 Dec;203(5):792-802. doi: 10.1111/bjh.19097. Epub 2023 Sep 10. Br J Haematol. 2023. PMID: 37691005 Clinical Trial.
Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group.
Paszkiewicz-Kozik E, Hus I, Palka M, Dębowska M, Końska A, Kotarska M, Tyczyńska A, Joks M, Twardosz M, Giza A, Wąsik-Szczepanek E, Kalicińska E, Wiśniewska A, Morawska M, Lewicka B, Szymański M, Targoński Ł, Romejko-Jarosińska J, Drozd-Sokołowska J, Subocz E, Swoboda R, Długosz-Danecka M, Lech-Maranda E, Walewski J. Paszkiewicz-Kozik E, et al. Among authors: tyczynska a. Adv Clin Exp Med. 2023 Jan;32(1):131-136. doi: 10.17219/acem/157290. Adv Clin Exp Med. 2023. PMID: 36603138 Free article.
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.
Dicanio M, Giaccherini M, Clay-Gilmour A, Macauda A, Sainz J, Machiela MJ, Rybicka-Ramos M, Norman AD, Tyczyńska A, Chanock SJ, Barington T, Kumar SK, Bhatti P, Cozen W, Brown EE, Suska A, Haastrup EK, Orlowski RZ, Dudziński M, Garcia-Sanz R, Kruszewski M, Martinez-Lopez J, Beider K, Iskierka-Jazdzewska E, Pelosini M, Berndt SI, Raźny M, Jamroziak K, Rajkumar SV, Jurczyszyn A, Vangsted AJ, Collado PG, Vogel U, Hofmann JN, Petrini M, Butrym A, Slager SL, Ziv E, Subocz E, Giles GG, Andersen NF, Mazur G, Watek M, Lesueur F, Hildebrandt MAT, Zawirska D, Ebbesen LH, Marques H, Gemignani F, Dumontet C, Várkonyi J, Buda G, Nagler A, Druzd-Sitek A, Wu X, Kadar K, Camp NJ, Grzasko N, Waller RG, Vachon C, Canzian F, Campa D. Dicanio M, et al. Among authors: tyczynska a. Int J Cancer. 2023 Jan 15;152(2):239-248. doi: 10.1002/ijc.34278. Epub 2022 Oct 1. Int J Cancer. 2023. PMID: 36082445 Free PMC article.
The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age.
Tyczyńska A, Krzempek MK, Cortez AJ, Jurczyszyn A, Godlewska K, Ciepłuch H, Subocz E, Hałka J, Kulikowska de Nałęcz A, Wiśniewska A, Świderska A, Waszczuk-Gajda A, Drozd-Sokołowska J, Guzicka-Kazimierczak R, Wiśniewski K, Porowska A, Knopińska-Posłuszny W, Kłoczko J, Rzepecki P, Woszczyk D, Symonowicz H, Basak GW, Zdziarska B, Jamroziak K, Zaucha JM. Tyczyńska A, et al. Cancers (Basel). 2023 Jul 2;15(13):3469. doi: 10.3390/cancers15133469. Cancers (Basel). 2023. PMID: 37444579 Free PMC article.
Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group.
Wróbel T, Biecek P, Rybka J, Szulgo A, Sorbotten N, Giza A, Tyczyńska A, Nowara E, Badora-Rybicka A, Adamowicz K, Kulikowski W, Kroll-Balcerzak R, Balcerzak A, Spychałowicz W, Kalinka-Warzocha E, Kumiega B, Drozd-Sokołowska J, Subocz E, Sałek A, Machaczka M, Hołojda J, Pogrzeba J, Dobrzyńska O, Chmielowska E, Jurczak W, Knopińska-Posłuszny W, Leśniewski-Kmak K, Maciej Zaucha J. Wróbel T, et al. Among authors: tyczynska a. Leuk Lymphoma. 2019 Feb;60(2):341-348. doi: 10.1080/10428194.2018.1482539. Epub 2018 Jul 6. Leuk Lymphoma. 2019. PMID: 29979097
Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a "real-world" study: experiences of the Polish Myeloma Group.
Charliński G, Tyczyńska A, Małecki B, Fornagiel S, Barchnicka A, Kołkowska A, Kopińska A, Usnarska-Zubkiewicz L, Robak P, Waszczuk-Gajda A, Krzystański M, Jurczyszyn A. Charliński G, et al. Among authors: tyczynska a. Pol Arch Intern Med. 2021 Jun 29;131(6):527-534. doi: 10.20452/pamw.15980. Epub 2021 Apr 28. Pol Arch Intern Med. 2021. PMID: 33908731 Free article.
First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, Szpila T, Butrym A, Giza A, Zaucha JM, Kalinka-Warzocha E, Wieczorkiewicz A, Zimowska-Curyło D, Knopińska-Posłuszny W, Tyczyńska A, Romejko-Jarosińska J, Dąbrowska-Iwanicka A, Gruszecka B, Jamrozek-Jedlińska M, Borawska A, Hołda W, Porowska A, Romanowicz A, Hellmann A, Stella-Hołowiecka B, Deptała A, Jurczak W. Walewski J, et al. Among authors: tyczynska a. Br J Haematol. 2020 Mar;188(6):898-906. doi: 10.1111/bjh.16264. Epub 2019 Dec 2. Br J Haematol. 2020. PMID: 31792945 Free PMC article. Clinical Trial.